Lipid core peptide/poly(lactic-co-glycolic acid) as a highly potent intranasal vaccine delivery system against Group A streptococcus

Marasini, Nirmal, Khalil, Zeinab G., Giddam, Ashwini K., Abdul Ghaffar, Khairunnisa, Hussein, Waleed M., Capon, Robert J., Batzloff, Michael R., Good, Michael F., Skwarczynski, Mariusz and Toth, Istvan (2016) Lipid core peptide/poly(lactic-co-glycolic acid) as a highly potent intranasal vaccine delivery system against Group A streptococcus. International Journal of Pharmaceutics, 513 1-2: 410-420. doi:10.1016/j.ijpharm.2016.09.057

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author Marasini, Nirmal
Khalil, Zeinab G.
Giddam, Ashwini K.
Abdul Ghaffar, Khairunnisa
Hussein, Waleed M.
Capon, Robert J.
Batzloff, Michael R.
Good, Michael F.
Skwarczynski, Mariusz
Toth, Istvan
Title Lipid core peptide/poly(lactic-co-glycolic acid) as a highly potent intranasal vaccine delivery system against Group A streptococcus
Journal name International Journal of Pharmaceutics   Check publisher's open access policy
ISSN 0378-5173
1873-3476
Publication date 2016-11-20
Sub-type Article (original research)
DOI 10.1016/j.ijpharm.2016.09.057
Open Access Status File (Author Post-print)
Volume 513
Issue 1-2
Start page 410
End page 420
Total pages 11
Place of publication Amsterdam, Netherlands
Publisher Elsevier
Collection year 2017
Language eng
Formatted abstract
Rheumatic heart disease represents a leading cause of mortality caused by Group A Streptococcus (GAS) infections transmitted through the respiratory route. Although GAS infections can be treated with antibiotics these are often inadequate. An efficacious GAS vaccine holds more promise, with intranasal vaccination especially attractive, as it mimics the natural route of infections and should be able to induce mucosal IgA and systemic IgG immunity. Nanoparticles were prepared by either encapsulating or coating lipopeptide-based vaccine candidate (LCP-1) on the surface of poly(lactic-co-glycolic acid) (PLGA). In vitro study showed that encapsulation of LCP-1 vaccine into nanoparticles improved uptake and maturations of antigen-presenting cells. The immunogenicity of lipopeptide incorporated PLGA-based nanoparticles was compared with peptides co-administered with mucosal adjuvant cholera toxin B in mice upon intranasal administration. Higher levels of J14-specific salivary mucosal IgA and systemic antibody IgG titres were observed for groups immunized with encapsulated LCP-1 compared to LCP-1 coated nanoparticles or free LCP-1. Systemic antibodies obtained from LCP-1 encapsulated PLGA NPs inhibited the growth of bacteria in six different GAS strains. Our results show that PLGA-based lipopeptide delivery is a promising approach for rational design of a simple, effective and patient friendly intranasal GAS vaccine resulting in mucosal IgA response.
Keyword Lipopeptides
Mucosal immunology
Nanoparticles
PLGA
Vaccine
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 4 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 4 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 07 Oct 2016, 20:04:36 EST by Mrs Louise Nimwegen on behalf of School of Chemistry & Molecular Biosciences